Increased risks seen for those with baseline hemochromatosis diagnoses and for those undiagnosed with hemochromatosis
Quality performance measure that tracks rates of follow-up within six months of abnormal SBT result is feasible, valid, reliable
Inappropriate diagnosis common, especially in older patients and those with dementia, altered mental status on presentation
For young patients, high boost dose yields slightly better local control, but increased incidence of fibrosis in boost area
Nonstatistically significant increase seen in prevalence of all birth defects collectively and in congenital heart disease